Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
:LTRN
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.49Last Year’s EPS
-0.51Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -19.62%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Neutral
Lantern Pharma has made notable advancements in AI-driven oncology drug development, achieving significant clinical trial milestones and regulatory designations. However, financial challenges persist with increased operational losses and future funding needs.Company Guidance
During the fourth quarter and fiscal year 2024 earnings call, Lantern Pharma provided a comprehensive update on its progress and strategic initiatives. The company highlighted significant advancements in its AI-driven precision oncology platform, RADR, which has enabled the rapid development of three AI-driven drugs into clinical trials. Notably, the Phase 2 HARMONIC trial for LP-300 demonstrated an 86% clinical benefit rate and a 43% objective response rate in non-small cell lung cancer patients who are never-smokers. The expansion into Japan and Taiwan is expected to accelerate enrollment for this $4 billion to $5 billion annual opportunity. Additionally, Lantern received FDA Fast Track designations for LP-184 in glioblastoma and triple-negative breast cancer, indicating potential for expedited development. Financially, the company reported R&D expenses of $4.3 million for Q4 2024, up from $3.6 million the previous year, and ended the year with $24 million in cash, cash equivalents, and marketable securities, providing a 12-month runway. The company plans to pursue additional funding opportunities in 2025 to support its ongoing operations and development efforts.AI and Machine Learning Integration
Lantern Pharma's leadership in using AI and machine learning to develop precision oncology therapies has been transformative, leading to significant advancements in their clinical pipeline and AI platform, RADR.
HARMONIC Trial Success
The HARMONIC trial for LP-300 reported an 86% clinical benefit rate and a 43% objective response rate in never-smoker non-small cell lung cancer patients, a significant achievement given the limited response to existing therapies.
Regulatory Achievements
Received two FDA Fast Track designations for LP-184 in glioblastoma and triple-negative breast cancer, along with three additional rare pediatric disease designations.
Strategic Geographic Expansion
Lantern Pharma expanded trials to Japan and Taiwan, accelerating patient enrollment due to higher incidence rates of non-small cell lung cancer among never-smokers.
---
LTRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LTRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $3.72 | $3.55 | -4.57% |
| Nov 07, 2024 | $3.42 | $3.84 | +12.28% |
| Aug 08, 2024 | $4.23 | $3.90 | -7.80% |
| May 09, 2024 | $6.81 | $6.16 | -9.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lantern Pharma, Inc. (LTRN) report earnings?
Lantern Pharma, Inc. (LTRN) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Lantern Pharma, Inc. (LTRN) earnings time?
Lantern Pharma, Inc. (LTRN) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LTRN EPS forecast?
LTRN EPS forecast for the fiscal quarter 2025 (Q1) is -0.49.
---